Who is on it, and how far along Every drug ChEMBL records acting on ADRM1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Small molecule 4 Protein or peptide 1 Approved3 Bortezomib Bortezomib SponsorTakeda Pharmaceuticals USA ModalitySmall molecule ActionInhibitor Open trials197 Carfilzomib Carfilzomib SponsorAmgen ModalityProtein or peptide ActionInhibitor Open trials97 Ixazomib citrate Ixazomib citrate SponsorTakeda Pharmaceuticals USA ModalitySmall molecule ActionInhibitor Open trials24 Phase 31 Ixazomib Ixazomib SponsorTakeda Pharmaceuticals USA ModalitySmall molecule ActionInhibitor Open trials24 Phase 21 Oprozomib Oprozomib SponsorAmgen ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: 26S proteasome inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 Bortezomib Phase 3 Not yet recruiting Qilu Pharmaceutical Co., Ltd. Nov 12, 2026 SKCD in Early Relapsed/Refractory Multiple Myeloma Carfilzomib Phase 2 Recruiting Beijing Chao Yang Hospital Nov 12, 2026 QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study Bortezomib Phase 2 Not yet recruiting Institute of Hematology & Blood Diseases Hospital, China Nov 6, 2026 To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Bortezomib Phase 3 Not yet recruiting Kite, A Gilead Company Oct 29, 2026 A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Bortezomib Phase 3 Not yet recruiting Janssen Research & Development, LLC Oct 29, 2026 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis Bortezomib Phase 3 Not yet recruiting Regeneron Pharmaceuticals Oct 28, 2026 Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma Bortezomib Phase 2 Recruiting Tata Memorial Centre Oct 23, 2026 Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Bortezomib Phase 2 / Phase 3 Not yet recruiting Alliance for Clinical Trials in Oncology Oct 22, 2026 A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Bortezomib Phase 3 Not yet recruiting Kite, A Gilead Company Oct 21, 2026 A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size Ixazomib, Ixazomib citrate Phase 2 Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) Oct 19, 2026 Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma Carfilzomib Phase 3 Recruiting CellCentric Ltd. Aug 19, 2026 A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Carfilzomib Phase 3 Recruiting AbbVie Jul 27, 2026 Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Carfilzomib Phase 1 Not yet recruiting National Cancer Institute (NCI) Jul 21, 2026 A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen Carfilzomib Phase 4 Not yet recruiting The First Affiliated Hospital of Soochow University Jul 17, 2026 KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome Carfilzomib Phase 2 Recruiting Shanghai Changzheng Hospital Jun 17, 2026 Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Carfilzomib Phase 2 Recruiting National Cancer Institute (NCI) May 26, 2026 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Carfilzomib Phase 3 Recruiting Hoffmann-La Roche Apr 29, 2026 SIL as Maintenance Therapy in Multiple Myeloma Ixazomib, Ixazomib citrate Phase 2 Not yet recruiting Navy General Hospital, Beijing Dec 20, 2024 Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma Ixazomib, Ixazomib citrate Phase 4 Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine Feb 10, 2023 Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Ixazomib, Ixazomib citrate Phase 1 / Phase 2 Active, not recruiting Columbia University Jul 11, 2022 A Study of NINLARO® in Chinese Adults With Multiple Myeloma Ixazomib, Ixazomib citrate — Active, not recruiting Takeda Aug 19, 2021 A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." Ixazomib, Ixazomib citrate Phase 2 Active, not recruiting Nantes University Hospital Aug 10, 2021 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Ixazomib, Ixazomib citrate Phase 1 Active, not recruiting National Cancer Institute (NCI) Apr 19, 2021 Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib Ixazomib, Ixazomib citrate Phase 2 Active, not recruiting Tel-Aviv Sourasky Medical Center Mar 10, 2021
Show all 24Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364701 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets